Comparative Pharmacology
Head-to-head clinical analysis: NEO CORTEF versus NEO HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO CORTEF versus NEO HYDELTRASOL.
NEO-CORTEF vs NEO-HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Hydrocortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Prednisolone, a glucocorticoid, binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including cytokines, prostaglandins, and leukotrienes. It also inhibits phospholipase A2 and reduces immune cell activity.
Apply a thin layer to the affected area 3 to 4 times daily. Use the 0.5% strength for mild conditions and 1% for more severe conditions.
4-20 mg intramuscularly, intravenously, intra-articularly, or intrasynovially every 12-24 hours; maximum initial dose 40 mg.
None Documented
None Documented
Terminal half-life 2-4 hours for neomycin; hydrocortisone half-life 1-2 hours. Clinical context: q6-8h dosing.
Terminal elimination half-life: 2.5–3.5 hours (adults). Note: The biologic half-life (duration of anti-inflammatory effect) is 18–36 hours due to persistence of glucocorticoid receptor-mediated effects.
Renal (70-80% as free drug and metabolites), fecal (20-30% via bile).
Renal: 50–80% as unchanged drug and metabolites (primarily as glucuronide and sulfate conjugates). Fecal/biliary: minor (<10%).
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic